ProCE Banner Activity

Biosimilars: Addressing Uncertainties With a New Drug Class

Clinical Thought
Biosimilars promise increased access and decreased prices for patients in need of expensive biologics. However, as with any new category of drug, biosimilars face some uncertainties. Here’s my take.

Released: March 13, 2017

Expiration: March 12, 2018

No longer available for credit.

Share

Faculty

Kenneth G. Saag

Kenneth G. Saag, MD, MSc

Jane Knight Lowe Professor
Division of Clinical Immunology and Rheumatology
Vice Chair, Department of Medicine
Director
Center for Education and Research on Therapeutics
Center for Outcomes, Effectiveness Research and Education
Center of Research Translation in Gout and Hyperuricemia
University of Alabama at Birmingham
Birmingham, Alabama

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Faculty Disclosure

Primary Author

Kenneth G. Saag, MD, MSc

Jane Knight Lowe Professor
Division of Clinical Immunology and Rheumatology
Vice Chair, Department of Medicine
Director
Center for Education and Research on Therapeutics
Center for Outcomes, Effectiveness Research and Education
Center of Research Translation in Gout and Hyperuricemia
University of Alabama at Birmingham
Birmingham, Alabama

Kenneth G. Saag, MD, MSc, has disclosed that he has received consulting fees from Abbott, Amgen, Ardea Biosciences/AstraZeneca, Bayer, Bristol-Myers Squibb, Merck, and Roche/Genentech.